Matches in SemOpenAlex for { <https://semopenalex.org/work/W2580616766> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W2580616766 endingPage "468" @default.
- W2580616766 startingPage "468" @default.
- W2580616766 abstract "468 Background: Renal cell carcinoma (RCC) is the third most common genitourinary cancer. Up to 30% of patients (pts) with RCC presents with advanced disease. Sunitinib(S), an orally available tyrosine kinase inhibitor, is the well established first-line therapy for these population. Actually few data are available in the literature about its use in patients > 75 yrs investigating the feasibility, the efficacy and the toxicity in this population. Methods: From 2007 to 2011, 16 pts >75 yrs with mRCC received S. 75% of pts had a clear cell carcinoma, 87.5% had a surgery on primary tumor, 18.7% had a metastic disease at diagnosis and the median time to metastatic progression was 13.5 months. Median age was 78 years (range 71-88y).All patients had 0-1 performance status and 69% of them received S as first-line treatment. Four pts started S on the approved 50 mg /d 4-week-on-2-off schedule, but three of them reduced to 37.5 mg continuous once daily dosing(ODD)starting from the third cycle. Five out of 8 pts receiving 37.5 mg continuous ODD reduced the dose at 25 mg continuous ODD or modified the schedule. Four pts started with 25 mg continuous ODD and 2 of them continued the treatment at modified schedule. Median number of cycles administered was 7 (range 2-16). Results: Response rate was 87% (13pts) in 15 evaluable pts. Overall response included 40% (6 pts) of PR, 20% (3pts) of CR, 33% (5pts) of SD > 6 mos. Progressive disease was observed only in 1patient. TTP was 12.4 months (95% CI, 4.8-32.6). Overall survival was 34.2 months (95% CI, 27.3- ). The main toxicity requiring dose reduction or schedule modification was haematological (46%), G3Anemia in 1 pt G3-4 thrombocytopenia in 3pts and G3 leukoneutrophenia in 3pts. No any toxicity required treatment interruption. Conclusions: In summary these results show the feasibility and the efficacy of S in elderly population with high response rate regardless the doses and schedule used." @default.
- W2580616766 created "2017-02-03" @default.
- W2580616766 creator A5007694366 @default.
- W2580616766 creator A5027676991 @default.
- W2580616766 creator A5036999191 @default.
- W2580616766 creator A5054816287 @default.
- W2580616766 creator A5084629809 @default.
- W2580616766 creator A5085512648 @default.
- W2580616766 creator A5013200959 @default.
- W2580616766 date "2012-02-10" @default.
- W2580616766 modified "2023-10-17" @default.
- W2580616766 title "Metastatic renal cell carcinoma (mRCC) in elderly patients: Can a personalized approach be an effective therapeutic option?" @default.
- W2580616766 doi "https://doi.org/10.1200/jco.2012.30.5_suppl.468" @default.
- W2580616766 hasPublicationYear "2012" @default.
- W2580616766 type Work @default.
- W2580616766 sameAs 2580616766 @default.
- W2580616766 citedByCount "0" @default.
- W2580616766 crossrefType "journal-article" @default.
- W2580616766 hasAuthorship W2580616766A5007694366 @default.
- W2580616766 hasAuthorship W2580616766A5013200959 @default.
- W2580616766 hasAuthorship W2580616766A5027676991 @default.
- W2580616766 hasAuthorship W2580616766A5036999191 @default.
- W2580616766 hasAuthorship W2580616766A5054816287 @default.
- W2580616766 hasAuthorship W2580616766A5084629809 @default.
- W2580616766 hasAuthorship W2580616766A5085512648 @default.
- W2580616766 hasConcept C126322002 @default.
- W2580616766 hasConcept C126894567 @default.
- W2580616766 hasConcept C141071460 @default.
- W2580616766 hasConcept C143998085 @default.
- W2580616766 hasConcept C2777288759 @default.
- W2580616766 hasConcept C2777472916 @default.
- W2580616766 hasConcept C2779490328 @default.
- W2580616766 hasConcept C2908647359 @default.
- W2580616766 hasConcept C71924100 @default.
- W2580616766 hasConcept C90924648 @default.
- W2580616766 hasConcept C99454951 @default.
- W2580616766 hasConceptScore W2580616766C126322002 @default.
- W2580616766 hasConceptScore W2580616766C126894567 @default.
- W2580616766 hasConceptScore W2580616766C141071460 @default.
- W2580616766 hasConceptScore W2580616766C143998085 @default.
- W2580616766 hasConceptScore W2580616766C2777288759 @default.
- W2580616766 hasConceptScore W2580616766C2777472916 @default.
- W2580616766 hasConceptScore W2580616766C2779490328 @default.
- W2580616766 hasConceptScore W2580616766C2908647359 @default.
- W2580616766 hasConceptScore W2580616766C71924100 @default.
- W2580616766 hasConceptScore W2580616766C90924648 @default.
- W2580616766 hasConceptScore W2580616766C99454951 @default.
- W2580616766 hasIssue "5_suppl" @default.
- W2580616766 hasLocation W25806167661 @default.
- W2580616766 hasOpenAccess W2580616766 @default.
- W2580616766 hasPrimaryLocation W25806167661 @default.
- W2580616766 hasRelatedWork W2056402925 @default.
- W2580616766 hasRelatedWork W2072245035 @default.
- W2580616766 hasRelatedWork W2154171266 @default.
- W2580616766 hasRelatedWork W2171237277 @default.
- W2580616766 hasRelatedWork W2322617799 @default.
- W2580616766 hasRelatedWork W2544140097 @default.
- W2580616766 hasRelatedWork W2551353941 @default.
- W2580616766 hasRelatedWork W3151554875 @default.
- W2580616766 hasRelatedWork W4205243027 @default.
- W2580616766 hasRelatedWork W4308744875 @default.
- W2580616766 hasVolume "30" @default.
- W2580616766 isParatext "false" @default.
- W2580616766 isRetracted "false" @default.
- W2580616766 magId "2580616766" @default.
- W2580616766 workType "article" @default.